E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
In many extremely preterm infants, the ductus arteriosus does not constrict itself. The ductus arteriosus is open. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Phase III: The primary objective is an increase in surviving without severe morbidity at 36 weeks of post menstrual age (or at discharge if it occurs before) from 50% (placebo group) to 60% in group receiving a prophylactic treatment by acetaminophen during the first 5 days of life. |
|
E.2.2 | Secondary objectives of the trial |
Phase III: -Early prophylactic treatment by acetaminophen decreases pain score and opiate consumption during the first 5 days of life. -Early prophylactic treatment by acetaminophen reduces the number of back-up treatment of PDA (NSAIDs, surgery, trans-catheter procedure) -Early prophylactic treatment by acetaminophen reduces catecholamines, opioid and parenteral nutrition requirements -Pharmacokinetics of acetaminophen (in 50 preterms). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
▪ Birth between 23-26 W for Phase II, between 23-28 W for Phase III ▪ Post natal age < 12 hours ▪ Parental or Legal Authority Consent ▪ Parents with a social security or health insurance (if applicable according to the local regulations) |
|
E.4 | Principal exclusion criteria |
▪ Parental refusal ▪ Birth defect / Congenital anomaly ▪ Twin-to-twin transfusion syndrome ▪ Suspicion of pulmonary hypoplasia - Suspicion of hepatic impairment (hemorrhagic syndrome and/or severe hypoglycemia) ▪ Clinical instability that can lead to rapid death ▪ Impossibility to start treatment before 12 hours of life ▪ Parents placed under judicial protection ▪ Participation in other clinical trial using acetaminophen during the first 5 days of life, indomethacin or ibuprofen during the first 3 days of life or using rescue treatment of PDA not recommended in the TREOCAPA trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint of phase III is the survival without severe morbidity at 36 weeks of post menstrual age or at first discharge home, whichever comes first. The severe morbidities include bronchopulmonary dysplasia (BPD Grade 3 according to NIH consensus), necrotizing enterocolitis (NEC) of Bell's stage II or III, intraventricular hemorrhage (IVH) grade III-IV or cystic leukomalacia observed at any time up to 36 weeks of post menstrual age. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary endpoint of phase III is evaluate at 36 weeks of post menstrual age or at first discharge home. |
|
E.5.2 | Secondary end point(s) |
Main secondary endpoints of phase III are: (1) Number of rescue treatment to close ductus by non steroid antiinflamatory drugs (NSAIDs) or by surgery or by transcatheter. (2) Diastolic systemic arterial pressure during the first week (3) Early and all Pulmonary hemorrhage (4) Cathecholamines, and opiate consumption during the first week of life (5) Volume of enteral nutrition during the first week of life (6) Interaction between parent involvement during the first week of life and medical care |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 36 weeks of post menstrual age or at first discharge home |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 65 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of completion of the last visit or procedure of the last participant. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |